Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection

Summary

This is an open-label Phase I study, four dose escalation groups, to evaluate the safety of CD24-exosomes in patients with moderate/severe COVID-19 disease. Patients with moderate/severe COVID-19 infection and factors predictive of a cytokine storm are recruited from the Corona department of the Tel Aviv Sourasky Medical Center (TASMC), who have provided informed consent are being recruited in four dose groups who will receive the exosome treatment as an add-on treatment to standard treatment.

Timeline

Start

2020-09-25

Primary completion

2021-02-25

Completion

2021-03-25

Drugs

Indications